久久久无码人妻精品无码_6080YYY午夜理论片中无码_性无码专区_无码人妻品一区二区三区精99

USEUROPEAFRICAASIA 中文雙語Fran?ais
China
Home / China / Business

Drug makers eye small cities

By Liu Jie | China Daily | Updated: 2011-12-21 07:52

Drug makers eye small cities
Assistants help a customer choose medicine at a pharmacy in Qionghai, Hainan province. Multinational drug makers are taking steps to enter the markets of smaller cities in China. [Meng Zhongde / For China Daily]

Country's health reforms open doors to foreign healthcare firms

BEIJING / SHANGHAI - As reform of China's medical care system makes its way down to some of the smaller cities in China, multinational pharmaceutical companies are turning their eyes to those places, while they may face challenges and uncertainties, analysts said.

This year, various international drug makers, including Bayer HealthCare, Pfizer Inc and Sanofi SA, announced plans to enter China's second-, third- and even fourth-tier cites. The pharmaceutical markets in such places are growing faster than in first-tier cities, which in the past have often been the places where growth was most rapid.

The businesses said they see a demand for their products in those cities, especially as the government's ongoing healthcare reform aims to provide universal medical care for the 1.3 billion population by 2020.

"Foreigners are moving into China's smaller markets because there is huge potential there," said Wang Youhong, an analyst with Haitong Securities. "At the current stage, having a vast rural market may be just a vision for them and entering smaller cities is more practical, because market conditions there are not very different from those in big cities and residents will accept new products with higher prices from multinational drug makers much more readily."

Bayer HealthCare, a subsidiary of Germany's Bayer AG, released its new plan for China in March, saying that it considers the huge Chinese market to be composed of three regions. Now, its central region is based in Beijing, the southern region has its base in Shanghai, and the western region is based in Chengdu.

"The strategy will enable us to be customer-centric, to disaggregate operational complexity, be more flexible and speed up operational decision-making at the frontline," said Chris H. Lee, managing director of Bayer HealthCare China.

"It will help us to stay close to front-line employees and be more attentive to their needs and development."

He said he believes the western region will grow faster than the others.

He also said the company will add 1,000 sales representatives to its Chinese workforce in 2011, an increase of 30 percent from a year before.

The plan calls for Bayer HealthCare to tailor its expansion plans to the conditions that are present in each of the three regions.

In 2010, each of its sales representatives generated 6.44 million yuan ($1 million) on average for the company. For the top 10 multinational drug makers in China, the average comparable amount was 4.39 million yuan, according to the R&D-based Pharmaceutical Association Committee, a nonprofit, non-governmental organization under the China Association of Enterprises.

So far, the plan has been progressing smoothly, the company said. Bayer HealthCare China is one of the top three multinational drug makers in the country measured by sales. In 2010, the value of its sales increased to 7.24 billion yuan, an increase of 22 percent from the year before. That momentum is expected to continue this year.

Pfizer, based in the United States, has also established a strong presence in large Chinese cities and is working with partners in the country to distribute its products to smaller cities.

In April, it signed a Memorandum of Understanding with the Shanghai Pharmaceutical (Group) Co Ltd to register, distribute and eventually sell a Pfizer product in China. The two sides also plan to work together to promote the use of Pfizer's Prevenar (7-valent), a pneumococcal conjugate vaccine. In June, Pfizer established a similar partnership with the Zhejiang Hisun Pharmaceutical Co Ltd and, in August, one with the Jointown Pharmaceutical Group Co Ltd, a Hubei-based company and one of the top five medicine distributors in China. As a result, Pfizer has been able to draw on its Chinese partners' resources and has gained entry to markets in the country's central and eastern regions.

For the first half of the year, Pfizer China reported sales revenue of $565 million, an increase of 24.6 percent above the same period a year before.

As for the French drug maker Sanofi, its business is developing quickly in China and other emerging markets; in 2010, its sales in emerging markets exceeded those in both the US and Europe.

That performance partly arose from selling the right products in those markets, said a report from IMS Health, an international medical care research firm.

Take Plavix, a cardiovascular medicine, and Lantus, an insulin treatment, as examples. Because they have been marketed well and carry fairly low prices, both can be found at hospitals and pharmacies in smaller cities. In 2010, 1.88 billion yuan worth of Plavix and 549 million yuan worth of Lantus were sold in China.

The enthusiasm of multinational drug makers for China's smaller cities is being driven in part by the medical reform that China has been undertaking since 2009.

In April 2009, China began acting on a plan to make comprehensive reforms to its medical system. The plan's eventual goal is to establish a universal healthcare system for the country by 2020, giving people both access to affordable public hospitals, clinics and similar places and coverage from public medical insurance.

The first phase of the plan is to be completed this year, providing medical care to 90 percent of the population. In 2010, an additional 12.3 billion yuan in government money was allocated toward the medial reforms. That came on top of the 850 billion yuan that was provided between 2009 and this year.

Stimulated by the reform and the population's ever-increasing demand for improved medical care, the value of the Chinese pharmaceutical market is expected to grow at an average annual rate of 20.1 percent between 2010 and 2015, reaching 694 billion yuan by 2015, IMS Health said.

After years of looking toward big cities in China, multinational companies have come to better understand the country's markets. Even so, many obstacles stand in the way of their entry into smaller cities, analysts said.

At the same time, multinational drug makers are expanding their sales force, further indicating their commitment to sales and marketing. The IMS report said the largest of the drug makers employs 3,500 sales representatives, stopping short of identifying the company.

So far, the chief difficulty for multinational companies that want to compete against Chinese companies will be in finding markets that offer the greatest potential for growth and in tailoring their products to meet the diverse needs of customers.

"Their domestic competitors have established both complete sales networks and sound relations with the governments and hospitals found in smaller markets, which is something that isn't easy for multinational companies to achieve in a short space of time," said Lydia Xu, a pharmaceutical researcher with the Samsung Economic Research Institute.

A shortage of talent is also causing headaches. According to research conducted by healthr.com - a medical job website - the demand for pharmaceutical workers in China's second- and third-tier cities increased greatly in the first quarter of the year.

During that period, the number of jobs in the medical industry in the city of Tianjin increased by 30.5 percent from a year before. The percentage increase between the same periods was 42.3 percent in Chongqing, 34.3 percent in Gansu province, 26 percent in the Ningxia Hui autonomous region and 38 percent in the Inner Mongolia autonomous region. A large proportion of the job opportunities, about 27.1 percent, were for sales representatives.

"Recruiting local people with good educations and medical experience is not easy," said a human resources manager from a multinational drug maker, who declined to give her name or that of her employer.

"Sending a sales team from headquarters, with people who are willing to work in smaller cities for the long term, is not practical because there are different cultural and social environments in those regions."

Some sales representatives from Chinese drug makers have taken to moving to multinational companies for better pay and training opportunities, giving such companies a good pool of talent to draw from in smaller cities. Doctors in hospitals serving such places are also good candidates.

China Daily

Drug makers eye small cities

Editor's picks
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
久久久无码人妻精品无码_6080YYY午夜理论片中无码_性无码专区_无码人妻品一区二区三区精99

    久久精品国产在热久久| 波多野结衣91| 久久久青草青青国产亚洲免观| 国产乱码精品1区2区3区| 中文字幕二三区不卡| 99久久精品情趣| 亚洲图片欧美色图| 日韩一二三四区| 国产成人啪免费观看软件| 亚洲视频一区二区在线| 欧美日韩免费视频| 精品一区二区国语对白| 国产精品久久影院| 欧美三级乱人伦电影| 久久精品国产精品亚洲红杏| 中文字幕av一区 二区| 在线欧美小视频| 另类中文字幕网| 中文字幕制服丝袜成人av | 亚洲激情第一区| 欧美一区二区三区系列电影| 国产精品一级在线| 一区二区三区在线免费视频| 日韩欧美一区二区免费| 成人av手机在线观看| 亚洲r级在线视频| 国产欧美一区二区三区在线老狼| 91国内精品野花午夜精品| 精品一二线国产| 亚洲激情自拍偷拍| 26uuu国产在线精品一区二区| 色一情一伦一子一伦一区| 免费观看日韩电影| 亚洲另类春色国产| 精品国产91久久久久久久妲己| 91麻豆国产自产在线观看| 激情五月婷婷综合| 一二三四社区欧美黄| 久久久噜噜噜久久中文字幕色伊伊| 欧美亚洲精品一区| 国产传媒欧美日韩成人| 午夜精品一区在线观看| 国产精品成人网| 精品日韩av一区二区| 一本一道久久a久久精品| 国产在线视频一区二区三区| 夜夜嗨av一区二区三区网页| 国产视频一区二区在线| 3d成人动漫网站| 91色porny蝌蚪| 韩国v欧美v亚洲v日本v| 亚洲图片一区二区| 18欧美亚洲精品| 久久久精品免费免费| 欧美精品乱码久久久久久按摩| eeuss鲁片一区二区三区在线看| 老司机免费视频一区二区| 亚洲激情图片qvod| 国产精品午夜电影| 精品国产sm最大网站| 4hu四虎永久在线影院成人| 色婷婷亚洲综合| 成人免费看的视频| 精品无人区卡一卡二卡三乱码免费卡 | 亚洲欧美日韩人成在线播放| 2021国产精品久久精品| 欧美疯狂性受xxxxx喷水图片| 日本韩国欧美一区二区三区| 成人爱爱电影网址| 国产高清精品在线| 久久精品72免费观看| 日韩电影在线观看一区| 午夜视频在线观看一区| 亚洲欧洲综合另类在线| 中文字幕高清不卡| 国产视频911| 久久久久久久综合| 精品成人一区二区| 91精品国产乱码| 欧美日韩国产一二三| 欧美视频在线不卡| 欧美午夜片在线观看| 在线观看视频一区二区| 一道本成人在线| 色综合久久久久综合体桃花网| 国产精品18久久久久久久久| 国产精品自拍毛片| 国产伦精品一区二区三区视频青涩 | 欧美日韩一区二区在线观看| 一本到三区不卡视频| gogo大胆日本视频一区| 成人午夜免费av| 丁香激情综合国产| 成人一区二区三区在线观看| 国产高清精品久久久久| 高清不卡一二三区| av中文字幕一区| 91色porny蝌蚪| 91久久一区二区| 欧洲av一区二区嗯嗯嗯啊| 在线中文字幕一区| 欧美日韩在线综合| 7777精品伊人久久久大香线蕉完整版| 欧美视频在线一区| 欧美一区日韩一区| 精品免费国产二区三区| 久久久亚洲高清| 国产嫩草影院久久久久| 国产精品每日更新| 亚洲免费三区一区二区| 亚洲韩国一区二区三区| 日本强好片久久久久久aaa| 琪琪一区二区三区| 激情欧美一区二区| 成人免费毛片片v| 色婷婷av一区二区| 欧美日韩亚洲综合一区 | 欧美一区二区在线免费播放 | 国产精品网友自拍| 综合精品久久久| 亚洲国产毛片aaaaa无费看| 午夜精品久久久久久久99水蜜桃 | 蜜桃av一区二区三区电影| 精品在线你懂的| 成人激情校园春色| 欧美中文字幕亚洲一区二区va在线| 欧美日韩免费视频| 精品国产a毛片| ㊣最新国产の精品bt伙计久久| 亚洲国产精品天堂| 美女看a上一区| 成人中文字幕电影| 欧美中文字幕亚洲一区二区va在线| 亚洲同性gay激情无套| 亚洲综合精品久久| 青青草97国产精品免费观看无弹窗版 | www国产成人| 国产精品国产馆在线真实露脸| 亚洲图片欧美色图| 激情图片小说一区| 91免费观看在线| 日韩一区二区在线观看视频| 国产欧美一区二区三区鸳鸯浴 | 午夜精品久久久久久久久久久| 九九九精品视频| 不卡视频一二三四| 欧美日韩中文精品| 久久亚洲精品小早川怜子| 亚洲欧美另类图片小说| 麻豆国产欧美日韩综合精品二区| 国产成人在线免费观看| 欧美亚一区二区| 精品国产乱码久久久久久久| 成人免费小视频| 捆绑调教一区二区三区| 色综合欧美在线视频区| 欧美不卡一区二区三区| 亚洲品质自拍视频网站| 九色porny丨国产精品| 91啪九色porn原创视频在线观看| 91精品国产综合久久香蕉麻豆| 国产片一区二区| 日本欧美一区二区在线观看| 99精品视频一区| 欧美精品一区在线观看| 一区二区在线看| 国产麻豆午夜三级精品| 欧美肥妇毛茸茸| 中文字幕一区二区三区色视频 | 国产人成一区二区三区影院| 亚洲一区二区三区四区的 | 日本韩国精品在线| 久久精品夜色噜噜亚洲aⅴ| 亚洲444eee在线观看| 成人免费视频app| 日韩精品一区二区三区三区免费| 亚洲精品国产一区二区精华液| 国产一区二区三区黄视频| 欧美午夜免费电影| 中文字幕欧美一| 国内精品写真在线观看| 欧美日本国产视频| 日韩毛片高清在线播放| 国产精品一区二区三区乱码| 91.麻豆视频| 一区二区在线观看视频| 国产成人鲁色资源国产91色综| 欧美一区二区三区成人| 亚洲影院免费观看| 99精品1区2区| 国产日韩视频一区二区三区| 麻豆91小视频| 欧美日韩国产精品自在自线| 亚洲视频一区二区在线| 懂色av一区二区三区免费看| 精品国产不卡一区二区三区| 丝袜美腿亚洲色图| 在线观看日产精品| 日韩美女视频19| av高清不卡在线|